Bausch+Lomb UK eye drop recall

Article

Minims Eye Drops Solution has been recalled in the UK only, reveals the latest statement from Bausch+Lomb.

Minims Eye Drops Solution has been recalled in the UK only, reveals the latest statement from Bausch+Lomb.

The recall on over 36,000 bottles of proxymetacaine 0.5% refers to batch #F50052 with an expiry date July 2014. It was initiated on 10 December 2012 and does not include the USA or Asia Pacific region.

Although there have been no reports of adverse events caused by the eye drops, Bausch+Lomb advise customers not to use them for safety reasons.

Alison Bunce, pharmaceutical assessor, Defective Medicines Report Centre, commented, "We chose to initiate this recall after confirming a report of the presence of foreign particles in product from this single lot. No adverse events have been reported which have been attributed to the defective product in this single lot. No other lots have been affected. No other products in the Minims range or other B+L products are affected by this action. We are working closely with the MHRA to provide updated information regarding this recall action."

For further details please call +44 208 781 2991

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.